Indivior Pharmaceuticals

INDV · NASDAQ

$34.77+$0.90 (+2.66%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $33.87

INDV analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $49.98 (+43.7% upside)

Low: $43.43
Now: $34.77
High: $55.65

Upgrades and downgrades

The latest rating actions, newest first

INDV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Aug 5, 2026	Maintains	Overweight	$46.00 → $43.00	53%
Barclays	Jun 18, 2026	Initiates	Overweight	$46.00	53%
HC Wainwright & Co.	Jan 12, 2026	Maintains	Buy	$35.00 → $48.00	36%
Piper Sandler	Oct 31, 2025	Maintains	Overweight	$27.00 → $41.00	68%
HC Wainwright & Co.	Oct 30, 2025	Maintains	Buy	$28.00 → $35.00	36%

The case for and against

Updated Apr 17, 2026

Bull case

Indivior Pharmaceuticals has demonstrated robust growth in its key product, Sublocade, with a significant increase in the number of patients treated, rising to approximately 171,500 in the third quarter of 2025, which signifies an 8% year-over-year growth. Additionally, the expansion in prescribers, increasing by 11% to around 8,568, reflects an improving acceptance and outreach for Sublocade, further supporting sales expectations of $825 million to $845 million for the year. The anticipated long-term growth trajectory, alongside effective cost control measures, positions Indivior favorably for continued sales expansion and potential multiple expansion in the coming years.

Bear case

Indivior Pharmaceuticals faces a negative outlook primarily due to a significant contraction in its operational footprint for Sublocade, which has been reduced to commercial support in only four countries from approximately forty. Additionally, the discontinuation of commercial support for Opvee highlights a lack of synergy with the company's core products, further consolidating its market presence. The anticipated ~6.5% revenue decline in 2026, as a result of the portfolio simplification actions expected in 2025, indicates ongoing challenges in revenue generation despite potential for improved EBITDA margins from Sublocade's growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.